Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer
BackgroundFor patients with extensive-stage small cell lung cancer (ES-SCLC), serplulimab plus chemotherapy is beneficial as the first-line treatment. It is uncertain whether serplulimab plus chemotherapy will be more cost-effective. The aim of this study was to evaluate from the perspective of the...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2023-08-01
|
| Col·lecció: | Frontiers in Public Health |
| Matèries: | |
| Accés en línia: | https://www.frontiersin.org/articles/10.3389/fpubh.2023.1156427/full |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|